Blocking the TGF-β signalling through a selective TGFβRI/II inhibitor (LY2109761) in canine OSA cell lines results in reduced cell proliferation, migration and VEGF secretion [24]. The gene discussed is VEGFA; the disease is obstructive sleep apnea syndrome.